The Absolute Effect / Oncology Evidence / Evidence Index
CheckMate 9LA
In untreated metastatic NSCLC without sensitizing EGFR/ALK alterations, does nivolumab-ipilimumab plus two cycles of chemotherapy improve overall survival over chemotherapy?
Registry: NCT03215706 · Evidence reviewed 9 November 2026 · Aliases and follow-up publications consolidated.
Phase III randomized open-label; n=719.Primary-source evidence summaryStudy design, population and eligibility
Phase III randomized open-label; n=719.
Treatment-naive stage IV/recurrent NSCLC without sensitizing EGFR/ALK alteration.
Treatment and comparator
Intervention: Nivolumab + ipilimumab + two cycles platinum-doublet chemotherapy.
Comparator: Four cycles platinum-doublet chemotherapy.
Endpoints
OS primary.
Key efficacy and clinical outcomes
At 6-y follow-up OS HR 0.74; 6-y OS 16% vs 10%; benefit across PD-L1 and histology.
Source-reported outcome visualization
Values are reproduced from the cited report; bars are scaled within this figure. First-line metastatic/recurrent NSCLC without sensitizing EGFR/ALK
Median survival and hazard ratios are not fixed-time event risks; NNT is not inferred from them.
Toxicity and treatment burden
Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies plus chemotherapy toxicity.
Absolute effect and NNT/NNH
Distinct from CheckMate 227: 9LA includes two chemotherapy cycles.
NNT/NNH is not calculated unless a directly reported, comparable fixed-time risk difference supports it. Median survival and hazard ratios alone do not provide an NNT.
Critical interpretation and limitations
Distinct from CheckMate 227: 9LA includes two chemotherapy cycles.
This page is an evidence summary, not a substitute for multidisciplinary assessment or patient-specific decision-making.
Current-practice context
Review date: 9 November 2026. Primary publication and selected follow-up sources were reviewed. Full disease-specific guideline, regulatory-label and sequencing audit remains pending; verify current local recommendations and biomarker eligibility before clinical application.